Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
E. Unti, S. Mazzucchi, G. Palermo, U. Bonuccelli & R. Ceravolo. (2017) Antipsychotic drugs in Huntington’s disease. Expert Review of Neurotherapeutics 17:3, pages 227-237.
Read now
Read now
Thomas Müller. (2017) Investigational agents for the management of Huntington’s disease. Expert Opinion on Investigational Drugs 26:2, pages 175-185.
Read now
Read now
Articles from other publishers (14)
Ferenc Bogár, Lívia Fülöp & Botond Penke. (2022) Novel Therapeutic Target for Prevention of Neurodegenerative Diseases: Modulation of Neuroinflammation with Sig-1R Ligands. Biomolecules 12:3, pages 363.
Crossref
Crossref
Michal Geva, Noga Gershoni-Emek, Luana Naia, Philip Ly, Sandra Mota, Ana Cristina Rego, Michael R. Hayden & Leonard A. Levin. (2021) Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma. Scientific Reports 11:1.
Crossref
Crossref
Shujun Chen, Tianyu Liang, Tao Xue, Shouru Xue & Qun Xue. (2021) Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Neurology 12.
Crossref
Crossref
Magdalena Jabłońska, Klaudyna Grzelakowska, Bartłomiej Wiśniewski, Ewelina Mazur, Kamil Leis & Przemysław Gałązka. (2020) Pridopidine in the treatment of Huntington’s disease. Reviews in the Neurosciences 31:4, pages 441-451.
Crossref
Crossref
Talya Shacham, Neeraj Sharma & Gerardo Z. Lederkremer. (2019) Protein Misfolding and ER Stress in Huntington's Disease. Frontiers in Molecular Biosciences 6.
Crossref
Crossref
Katya T Potkin & Steven G Potkin. (2018) New directions in therapeutics for Huntington disease. Future Neurology 13:2, pages 101-121.
Crossref
Crossref
Isha Monga, Abid Qureshi, Nishant Thakur, Amit Kumar Gupta & Manoj Kumar. (2017) ASPsiRNA: A Resource of ASP-siRNAs Having Therapeutic Potential for Human Genetic Disorders and Algorithm for Prediction of Their Inhibitory Efficacy. G3 Genes|Genomes|Genetics 7:9, pages 2931-2943.
Crossref
Crossref
Cristina Sánchez-Castañeda, Francesco de Pasquale, Chiara Falletta Caravasso, Massimo Marano, Sabrina Maffi, Simone Migliore, Umberto Sabatini & Ferdinando Squitieri. (2017) Resting-state connectivity and modulated somatomotor and default-mode networks in Huntington disease. CNS Neuroscience & Therapeutics 23:6, pages 488-497.
Crossref
Crossref
Abhijit Dey. 2017. Neuroprotective Natural Products. Neuroprotective Natural Products
185
246
.
Emma M. Coppen & Raymund A. C. Roos. (2016) Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease. Drugs 77:1, pages 29-46.
Crossref
Crossref
Claudia Rangel-Barajas & George V. Rebec. (2016) Dysregulation of Corticostriatal Connectivity in Huntington’s Disease: A Role for Dopamine Modulation. Journal of Huntington's Disease 5:4, pages 303-331.
Crossref
Crossref
Qinqin Wang, Qinbo Zhou, Shuzhen Zhang, Wei Shao, Yanqing Yin, Yandong Li, Jincan Hou, Xinhua Zhang, Yongshun Guo, Xiaomin Wang, Xiaosong Gu & Jiawei Zhou. (2016) Elevated Hapln2 Expression Contributes to Protein Aggregation and Neurodegeneration in an Animal Model of Parkinson's Disease. Frontiers in Aging Neuroscience 8.
Crossref
Crossref
Abhishek Chandra, Abhijeet Sharma, Noel Y. Calingasan, Joshua M. White, Yevgeniya Shurubor, X. William Yang, M. Flint Beal & Ashu Johri. (2016) Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington’s disease. Human Molecular Genetics 25:11, pages 2269-2282.
Crossref
Crossref
Tsung-Ping Su, Tzu-Chieh Su, Yoki Nakamura & Shang-Yi Tsai. (2016) The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends in Pharmacological Sciences 37:4, pages 262-278.
Crossref
Crossref